Logo image of OSE.PA

OSE IMMUNO (OSE.PA) Stock Price, Quote, News and Overview

EPA:OSE - Euronext Paris - Matif - FR0012127173 - Common Stock - Currency: EUR

4.95  -0.17 (-3.32%)

OSE.PA Quote, Performance and Key Statistics

OSE IMMUNO

EPA:OSE (7/7/2025, 7:00:00 PM)

4.95

-0.17 (-3.32%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High11.58
52 Week Low4.42
Market Cap110.63M
Shares22.35M
Float16.34M
Yearly DividendN/A
Dividend YieldN/A
PE2.89
Fwd PE11.95
Earnings (Next)09-24 2025-09-24
IPO03-30 2015-03-30


OSE.PA short term performance overview.The bars show the price performance of OSE.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15 -20 -25

OSE.PA long term performance overview.The bars show the price performance of OSE.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 60

The current stock price of OSE.PA is 4.95 EUR. In the past month the price decreased by -10.33%. In the past year, price decreased by -31.63%.

OSE IMMUNO / OSE Daily stock chart

OSE.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 18.4 284.74B
AMG.DE AMGEN INC 14.16 134.80B
GIS.DE GILEAD SCIENCES INC 14.4 118.26B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 100.27B
1VRTX.MI VERTEX PHARMACEUTICALS INC 1538.4 98.76B
ARGX.BR ARGENX SE 102.3 28.48B
22UA.DE BIONTECH SE-ADR N/A 22.65B
IDP.DE BIOGEN INC 8.29 16.38B
0QF.DE MODERNA INC N/A 10.00B
1MRNA.MI MODERNA INC N/A 9.97B
GLPG.AS GALAPAGOS NV N/A 1.59B
YTSN.DE KUROS BIOSCIENCES AG-REG N/A 1.18B

About OSE.PA

Company Profile

OSE logo image OSE Immunotherapeutics SA s is a biotechnology company, which engages in the research and development of pharmaceutical products. The company is headquartered in Nantes, Pays De La Loire. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.

Company Info

OSE IMMUNO

22, boulevard Benoni Goullin

Nantes PAYS DE LA LOIRE FR

Employees: 52

OSE Company Website

OSE Investor Relations

Phone: 33228291010

OSE IMMUNO / OSE.PA FAQ

What is the stock price of OSE IMMUNO today?

The current stock price of OSE.PA is 4.95 EUR. The price decreased by -3.32% in the last trading session.


What is the ticker symbol for OSE IMMUNO stock?

The exchange symbol of OSE IMMUNO is OSE and it is listed on the Euronext Paris - Matif exchange.


On which exchange is OSE.PA stock listed?

OSE.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for OSE IMMUNO stock?

9 analysts have analysed OSE.PA and the average price target is 16.83 EUR. This implies a price increase of 240% is expected in the next year compared to the current price of 4.95. Check the OSE IMMUNO stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is OSE IMMUNO worth?

OSE IMMUNO (OSE.PA) has a market capitalization of 110.63M EUR. This makes OSE.PA a Micro Cap stock.


How many employees does OSE IMMUNO have?

OSE IMMUNO (OSE.PA) currently has 52 employees.


What are the support and resistance levels for OSE IMMUNO (OSE.PA) stock?

OSE IMMUNO (OSE.PA) has a support level at 4.94 and a resistance level at 4.96. Check the full technical report for a detailed analysis of OSE.PA support and resistance levels.


Is OSE IMMUNO (OSE.PA) expected to grow?

The Revenue of OSE IMMUNO (OSE.PA) is expected to decline by -47.32% in the next year. Check the estimates tab for more information on the OSE.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy OSE IMMUNO (OSE.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does OSE IMMUNO (OSE.PA) stock pay dividends?

OSE.PA does not pay a dividend.


When does OSE IMMUNO (OSE.PA) report earnings?

OSE IMMUNO (OSE.PA) will report earnings on 2025-09-24.


What is the Price/Earnings (PE) ratio of OSE IMMUNO (OSE.PA)?

The PE ratio for OSE IMMUNO (OSE.PA) is 2.89. This is based on the reported non-GAAP earnings per share of 1.71 and the current share price of 4.95 EUR. Check the full fundamental report for a full analysis of the valuation metrics for OSE.PA.


OSE.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

OSE.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to OSE.PA. OSE.PA has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

OSE.PA Financial Highlights

Over the last trailing twelve months OSE.PA reported a non-GAAP Earnings per Share(EPS) of 1.71. The EPS increased by 245.42% compared to the year before.


Industry RankSector Rank
PM (TTM) 44.88%
ROA 30.21%
ROE 58.68%
Debt/Equity 0.6
Chartmill High Growth Momentum
EPS Q2Q%-66.06%
Sales Q2Q%-0.81%
EPS 1Y (TTM)245.42%
Revenue 1Y (TTM)3646.52%

OSE.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to OSE.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of -82.85% and a revenue growth -47.32% for OSE.PA


Ownership
Inst Owners3.11%
Ins Owners24.93%
Short Float %N/A
Short RatioN/A
Analysts
Analysts82.22
Price Target16.83 (240%)
EPS Next Y-82.85%
Revenue Next Year-47.32%